Last updated on April 16, 2014 at 21:24 EDT

Latest The SFJ Pharmaceuticals Group Stories

2012-09-07 02:24:04

SAN FRANCISCO, September 7, 2012 /PRNewswire/ -- Phase 3 Trial to be Conducted Across Sites in Asia and Europe The SFJ Pharmaceuticals Group (SFJ), announced today that it has entered into a collaborative development agreement with Pfizer Inc. to conduct a Phase 3 clinical trial of Pfizer's investigational pan-HER (pan-human epidermal growth factor receptor) inhibitor, dacomitinib (PF-00299804). The trial, which will be conducted across multiple sites in Asia...